Awarded· 20 Oct 2025
NHS Genomic Medicine Service - Most Suitable Provider Process
NHS England · Leeds, Yorkshire and the Humber
NHS England has awarded NHS Genomic Medicine Service - Most Suitable Provider Process. It is a contract for other health and social care in Leeds.
Source: Find a Tender, published 23 Oct 2025. Details are refreshed every 30 minutes.
Key dates
2025
Pipeline notice published
Planning Notice · 16:52
View notice2025
Contract awarded
2025
Award notice published
Award Notice · 16:00
View notice
About this tender
In brief
NHS England has awarded NHS Genomic Medicine Service - Most Suitable Provider Process. It is a contract for other health and social care in Leeds. It was awarded on 20 October 2025. The estimated value is £3,850,000,000. It is split across 7 lots.
It is run as an award procedure without prior publication of a call for competition. Find a Tender published it on 23 October 2025. The notice number is 067976-2025. The OCDS ID is ocds-h6vhtk-0565e9.
Summary of the contracting process
The NHS Genomic Medicine Service (NHS GMS) tender, managed by NHS England, is a significant procurement process aiming to enhance health services across various regions in the United Kingdom. With an estimated total contract value of £5,175,000,000, the services are anticipated to commence on 1st April 2026 and could extend until 31st March 3036.
The procurement is segmented into seven distinct Lots, targeting geographic areas like North-West, North-East and Yorkshire, Central and South, with NHS organisations positioned as potential providers. This notice reflects the intention to award under the Provider Selection Regime, highlighting key dates such as the standstill period resulting from the publication on 23rd October 2025 and a deadline for representations by 4th November 2025.
The procurement is conducted through a limited procedure, bypassing prior competition calls. It is designed for entities that can demonstrate advanced capabilities in genomic testing, clinical pathways for cancer and rare diseases, and integration of data infrastructure. By enabling expansion in genomic innovation and service delivery, the tender is particularly suited for large-scale NHS suppliers ready to collaborate and leverage existing clinical governance structures.
The notice in full
This is a notice of intention to make an award in respect of the NHS Genomic Medicine Service pursuant to the Most Suitable Provider (MSP) Process for the NHS Genomic Medicine Service (NHS GMS). For the avoidance of doubt, this is an intention to award notice. A notice of the confirmation of the award of each contract will be issued once they are signed.
Pursuant to the NHS GMS contracts, provider are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
Lots (7)
- 01
Lot 1 - NHS North-West GMSCancelled
Pursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot.
The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
- 02
Lot 2 - NHS North-East and Yorkshire GMSCancelled
Pursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot.
The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
- 03
Lot 3 - NHS Central and South GMSCancelled
Pursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot.
The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
- 04
Lot 4 - NHS East GMSCancelled
Pursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot.
The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
- 05
Lot 5 - NHS South-West GMSCancelled
Pursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot.
The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
- 06
Lot 6 - NHS North Thames GMSCancelled
Pursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot.
The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
- 07
Lot 7 - NHS South-East GMSCancelled
Pursuant to the NHS GMS contracts, providers are to provide the following functions:
* Organisational leadership, governance and partnership arrangements;
* Delivery of genomic testing outlined in the National Genomic Test Directory (NGTD);
* Laboratory operating model;
* Clinical function: cancer genomics;
* Clinical function: rare disease;
* Clinical function: population health;
* Promotion of and supporting and leading where relevant science, research and / or innovation;
* Transformation and Service Improvement;
* People - workforce, education and training; and
* Data and digital
The Commissioner intends to award contracts following the Most Suitable Process to 7 providers which are existing providers. This is an expansion of existing services which, under PSR, constitutes a new service.
The approximate lifetime value of the contract for all Lots is PS5,175,000,000.
The services will start on 1st April 2026 and the initial period will run until 31st March 3034 with an option to extend for up to a further 2 years (of 2 x 12 month periods).
Please note that the figure included in the 'Awarded Value' section of this part of the notice is the total approximate lifetime value of all Lots of the NHS Genomic Medicine Service contract. For the avoidance of doubt, this is not the approximate lifetime value for each Lot.
The approximate lifetime value for each Lot shall be included within the confirmation of contract award notice (which shall be issued once contracts have been signed).
Key facts
Contract
- Service
- Other
- Procurement type
- Standard
- Category
- Services
- Contract period
- Not specified - Not specified
- Lots
- 7
- Number of suppliers
- 7
Procedure
- Notice type
- Planning Notice
- Procurement method
- Limited
- Procedure
- Award procedure without prior publication of a call for competition
- Current stage
- Award
- Stages so far
- Planning, Award
- Published on
- Find a Tender Service
- Awardee scale
- Large
- Buyer's portal
- Atamis
Values
- Tender value
- £3,850,000,000
- Contracts value
- £5,175,000,000
Not stated in the notice: lots value, awards value.
Status
- Tender
- Complete
- Lots
- Cancelled
- Awards
- Active
- Contracts
- Active
References
- Find a Tender notice
- 067976-2025
- Open Contracting ID
- ocds-h6vhtk-0565e9
- CPV code
- 85100000 - Health services
- CPV division
- 85 - Health and social work services
Location
- Local authority
- Leeds
- Town
- Leeds
- Postcode
- LS1 4AP
- Electoral ward
- Hunslet & Riverside
- Constituency
- Leeds South
- Delivery area
- North East (England), TLD North West (England), TLF East Midlands (England), TLG West Midlands (England), TLH East (England), TLI London, TLJ South East (England), TLK South West (England)
- Region
- Yorkshire and the Humber
- Sub-region
- Leeds
- Area
- West Yorkshire
- Country
- England
Buyer
Contracting authority
- Organisation
- NHS England
- Category
- Services
- Contact
- Anna Salt
- Address
- Leeds, LS1 4AP · Yorkshire and the Humber · England
Not stated in the notice: phone.
Documents and links
Questions about NHS Genomic Medicine Service - Most Suitable Provider Process
Who won the NHS Genomic Medicine Service - Most Suitable Provider Process contract?
The award notice does not name the supplier. The full record is in the official notice linked on this page.
How much is the NHS Genomic Medicine Service - Most Suitable Provider Process contract worth?
The estimated value is £3,850,000,000, split across 7 lots.
Who is the buyer for NHS Genomic Medicine Service - Most Suitable Provider Process?
NHS England, based in Leeds, Yorkshire and the Humber. The named contact is Anna Salt.
Get ready for the next round
Contracts like this come back. We help care providers build the evidence, policies and case studies a buyer scores, so you are ready when the re-tender opens.
What to do next
- This contract has been awarded.
- A re-tender usually follows near the end.
- Build your evidence and case studies now.
- Keep your policies and training records current.
Bidding for contracts like this
Other tenders in Leeds
- Provision of Block Funded Respite Bed at Oakwood Hall Residential HomeLeeds
- Life Long Links ProgrammeLeeds
- PET-CT ServicesLeeds
- Employee Assistance Programme and associated additional servicesLeeds
- Day Services for Younger People Living With DementiaLeeds
- Hyperbaric Oxygen Therapy (HBOT) Services for all ages - Most Suitable Provider ProcessLeeds
- NEYPPC-High Tech Homecare Medicines Service(2025)Leeds
- Homecare ServicesLeeds
Browse by sector
- All open health and social care tendersThe full feed, updated every 30 minutes.
- Tender sectors we coverWhat each sector buys and how bids are scored.
- Supported living tendersSupport for adults in their own tenancies.
- Extra care tendersHousing with care staff on site.
- Reablement tendersShort-term help to regain everyday skills.
- Residential care and care home tendersCare home and nursing home beds.
- Domiciliary care tendersCare visits in people's own homes.
- Children and young people tendersChildren's homes, placements and short breaks.
Get help with your bid
- Health and social care tender writingWe write and review your bid.
- Guidance on managing a bidPlan a bid from notice to submission.
- Providers we have helped win contractsContracts our clients have won.
- What the Procurement Act 2023 changes for care tenders
- Book a consultation about this tenderTalk this tender through with us.